This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Terajima, M.
Right arrow Articles by Ennis, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Terajima, M.
Right arrow Articles by Ennis, F. A.

 Previous Article  |  Next Article 

Journal of Virology, September 2008, p. 9283-9287, Vol. 82, No. 18
0022-538X/08/$08.00+0     doi:10.1128/JVI.01047-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Influenza A Virus Matrix Protein 1-Specific Human CD8+ T-Cell Response Induced in Trivalent Inactivated Vaccine Recipients {triangledown}

Masanori Terajima,* John Cruz, Anita M. Leporati, Laura Orphin, Jenny Aurielle B. Babon, Mary Dawn T. Co, Pamela Pazoles, Julie Jameson,{dagger} and Francis A. Ennis

Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655

Received 19 May 2008/ Accepted 3 July 2008

Among 17 HLA-A2-positive healthy adults, CD8+ T-cell responses against an HLA-A2-restricted matrix protein 1 (M1) epitope increased after immunization with trivalent inactivated influenza vaccine (TIV) in two individuals. The presence of M1 in TIV was confirmed by Western blotting. T-cell cytotoxicity assays showed that TIV is processed and the epitope is presented by antigen-presenting cells to an M1 epitope-specific CD8+ T-cell line for specific lysis. These data show that TIV, which is formulated to contain surface glycoproteins to induce serotype-specific antibody responses, also contains M1, capable of inducing subtype cross-reactive CD8+ T-cell responses in some vaccinees.

* Corresponding author. Mailing address: Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655. Phone: (508) 856-4182. Fax: (508) 856-4890. E-mail: masanori.terajima{at}umassmed.edu

{triangledown} Published ahead of print on 9 July 2008.

{dagger} Present address: Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037.

Journal of Virology, September 2008, p. 9283-9287, Vol. 82, No. 18
0022-538X/08/$08.00+0     doi:10.1128/JVI.01047-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»